Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
2,656,706
-
Share change
-
+831,235
-
Total reported value
-
$5,066,902
-
Put/Call ratio
-
104%
-
Price per share
-
$1.91
-
Number of holders
-
32
-
Value change
-
+$1,576,755
-
Number of buys
-
22
-
Number of sells
-
3
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q1 2025
As of 31 Mar 2025,
Gain Therapeutics, Inc. - COM (GANX) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,656,706 shares.
The largest 10 holders included
DME Capital Management, LP, JONES FINANCIAL COMPANIES LLLP, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, MARSHALL WACE, LLP, Dauntless Investment Group, LLC, NORTHERN TRUST CORP, MORGAN STANLEY, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and BlackRock, Inc..
This page lists
32
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.